📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Journal Papers
Narrow Spectrum Kinase Inhibitors: Treating COPD and Steroid-Resistant Asthma
Experience therapeutic potential with narrow spectrum kinase inhibitors for COPD and steroid-resistant asthma.
Journal Papers
Facile access to a heterocyclic, sp3-rich chemical scaffold via a tandem condensation/intramolecular nitrone–alkene [3+2] cycloaddition strategy
Scaffolds of natural products represent promising starting points for the development of focused compound libraries
Journal Papers
Synthesis of a hexahydropyrrolo indole (HPI) compound library
Synthesis of a Hexahydropyrrolo Indole (HPI) Compound Library: Creating a diverse 276-member library based on HPI scaffold.
News
Towards the Holy Grail of Computational Chemistry
Dr. Steve St-Gallay – Principal Scientist, Computational Chemistry The Holy Grail of computational chemistry is…
Blog
Towards the Holy Grail of Computational Chemistry
By Dr. Steve St-Gallay – Principal Scientist, Computational Chemistry The Holy Grail of computational…
News
Sygnature Discovery establishes US Office in Cambridge, MA
Sygnature Discovery is continuing the expansion of its operations with the opening of its first…
News
Sygnature Discovery in the final of the 6th National RSC/SCI Retrosynthesis competition
A team of Sygnature Discovery chemists has made it to the final of the…
News
Pathios Therapeutics and Sygnature Discovery sign strategic partnership
Pathios Therapeutics and Sygnature Discovery sign strategic partnership to discover novel GPR65 modulators for the…
Blog
Where’s my chemical?
Time is money in drug discovery, so anything that avoids wasted time – however…
News
Sygnature Discovery Extends Ongoing Support to the European Lead Factory with the ESCulab Project
The European Lead Factory, Europe’s largest collaborative drug discovery platform, continues its success story The…
Blog
Designing Cancer Drugs – the Scientist vs Patient Perspective
When designing a new medicine, there are many properties that spring to the minds of…
Blog
The Rule of 5 – Two decades later
It’s now over 20 years since Pfizer’s Chris Lipinski introduced the Rule of 5 to…
News
Sygnature Discovery test-drives SPR-M
Our bioscientists have just completed the evaluation of an exciting new instrument at the interface…
Blog
Do new cancer treatments mean cancer patients live longer?
In recent years, we have made great strides in cancer treatment. In study after study,…
Blog
Towards an in vitro assay for fibrosis research
Sygnature Discovery is creating 2D and 3D assays for rapid testing of anti-fibrotic compounds. These validated in vitro models aim to predict in vivo efficacy and improve drug discovery success rates for fibrosis treatments. Collaborating with RenaSci, they offer a seamless approach from target validation to proof-of-concept. These models accelerate research efforts to address the unmet medical need of fibrosis.
Blog
The dose maketh the poison. Or the cure?
Back in the early 1500’s, the efficacy and toxicity of remedies were largely uninvestigated qualities.
Blog
Cleaning out disease – PROTACs on the rise
Discover the potential of PROTACs – a novel approach to targeted drug treatment. Learn how they exploit cells' protein destruction mechanism to destroy disease-causing proteins. Explore advantages over traditional drugs and their application in treating neurodegenerative diseases. Join the excitement around PROTACs' future and reach out to us for more information on drug discovery capabilities.
Blog
How come we landed on the moon within a decade, but still haven’t beaten cancer?
More than half a century after man’s first step on the moon, our Vice President…
Blog
Metabolite characterisation to accelerate drug discovery
The identification and characterisation of metabolites is a critical part of the drug discovery process.
Journal Papers
Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia
Uncover a novel anti-leukaemic compound derived from parthenolide, addressing drug-resistant CLL.
News
Ground-breaking anti-cancer compound derived from feverfew.
In collaboration with Sygnature Discovery, researchers at the University of Birmingham have shown that…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch